ABCG2 and hepatocellular carcinoma: This is achieved by inhibiting the efflux of ABCG2-dependent drugs and elevating intracellular DOX concentration via miR-519c, subsequently inhibiting tumor growth and achieving desirable therapeutic effects in HCC animal studies [44].